The FASEB Journal, Vol 7, 1055-1060, Copyright © 1993 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis

P Hayry, A Raisanen, J Ustinov, A Mennander and T Paavonen
Transplantation Laboratory, University of Helsinki, Finland.

Chronic rejection is the most common reason for late loss of a transplant. The molecular mechanism of chronic rejection is not known and there is no treatment for this disorder. The characteristic histological feature in chronic rejection is increased smooth muscle cell replication in the vascular wall, leading to allograft arteriosclerosis. In this study we demonstrate that nonimmunosuppressed rat aortic allografts undergoing chronic rejection synthesize increased quantities of several smooth muscle cell growth-promoting substances in the vascular wall including interleukin-1, eicosanoids, and several peptide growth factors. Administration of a stable somatostatin analog lanreotide, BIM 23014, strongly inhibits myocyte proliferation in the allograft in vivo. It has no inhibitory effect on the proliferation of smooth muscle cells in vitro. Concomitantly, the locally produced peptide growth factors, i.e., epidermal growth factor, insulin-like growth factor 1, and BB-isomer of platelet-derived growth factor, but not other mediators of inflammation, are significantly reduced. The results suggest that growth factors are the main effector molecules leading to myocyte proliferation in allograft arteriosclerosis and that allograft arteriosclerosis (chronic rejection) may be specifically inhibited by lanreotide administration.

This article has been cited by other articles:

				C Susini and L Buscail Rationale for the use of somatostatin analogs as antitumor agents Ann. Onc., December 1, 2006; 17(12): 1733 - 1742. [Abstract] [Full Text] [PDF]

				S. KHARE, U. KUMAR, R. SASI, L. PUEBLA, L. CALDERON, K. LEMSTROM, P. HAYRY, and A. Y. C. PATEL Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty FASEB J, February 1, 1999; 13(2): 387 - 394. [Abstract] [Full Text]

				G. Van Assche, I. Depoortere, R. De Vos, K. Geboes, J. J. Janssens, S. M. Collins, and T. L. Peeters Region-specific antiproliferative effect of VIP and PACAP-(1---38) on rabbit enteric smooth muscle Am J Physiol Gastrointest Liver Physiol, January 1, 1999; 276(1): G303 - G310. [Abstract] [Full Text] [PDF]

				M. A. Turman and C. A. Apple Human proximal tubular epithelial cells express somatostatin: regulation by growth factors and cAMP Am J Physiol Renal Physiol, June 1, 1998; 274(6): F1095 - F1101. [Abstract] [Full Text] [PDF]

				A. Raisanen-Sokolowski, T. Glysing-Jensen, P. L. Mottram, and M. E Russell Sustained Anti-CD4/CD8 Treatment Blocks Inflammatory Activation and Intimal Thickening in Mouse Heart Allografts Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 2115 - 2122. [Abstract] [Full Text]